Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity

被引:50
作者
Haykin, ME
Gorman, M
van Hoff, J
Fulbright, RK
Baehring, JM
机构
[1] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA
[2] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06510 USA
[3] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA
[4] Yale Univ, Sch Med, Dept Diagnost Radiol, New Haven, CT 06510 USA
关键词
DWI; methotrexate; subacute neurotoxicity;
D O I
10.1007/s11060-005-9569-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: A delayed stroke-like leukoencephalopathy has been observed in patients receiving methotrexate (MTX) for childhood leukemia. Diffusion-weighted MRI (DWI) may help to distinguish between ischemic stroke and chemotherapy-related leukoencephalopathy. Although conventional MRI correlates have been described for this stroke-like syndrome, DWI data are largely unavailable. Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered subacute neurotoxicity after intrathecal MTX. Design: We reviewed the medical records of four patients, who were seen by us between July 2000 and February 2004 for sudden onset of a central neurological syndrome within days of intrathecal MTX. Patients underwent standardized MRI within 48 h of symptom onset; MRI included DWI and apparent diffusion coefficient (ADC) maps. Results: DWI of all patients revealed well-demarcated hyperintense lesions within the subcortical white matter corresponding to areas of restricted proton diffusion on ADC maps. Lesions exceeded the confines of adjacent vascular territories. Complete resolution of symptoms within 1-4 days was accompanied by normalization of ADC abnormalities. Conclusions: DWI findings in this cohort seem to reflect cytotoxic edema within cerebral white matter suggesting a reversible metabolic derangement, rather than ischemia, as the basis for this syndrome.
引用
收藏
页码:153 / 157
页数:5
相关论文
共 26 条
  • [21] ACUTE REVERSIBLE NEUROTOXICITY AFTER INTRATHECAL LOW-DOSE METHOTREXATE
    SCHWEITZER, DH
    EDELBROEK, PM
    DEWOLFF, FA
    KEIZER, HJ
    [J]. EUROPEAN JOURNAL OF CANCER, 1991, 27 (02) : 219 - 220
  • [22] Subacute leukencephalopathy after low-dose intrathecal methotrexate in an adolescent heterozygous for the MTHFR C677T polymorphism
    Strunk, T
    Gottschalk, S
    Goepel, W
    Bucsky, P
    Schultz, C
    [J]. MEDICAL AND PEDIATRIC ONCOLOGY, 2003, 40 (01): : 48 - 50
  • [23] Tievsky AL, 1999, AM J NEURORADIOL, V20, P1491
  • [24] Biochemical and clinical aspects of methotrexate neurotoxicity
    Vezmar, S
    Becker, A
    Bode, U
    Jaehde, U
    [J]. CHEMOTHERAPY, 2003, 49 (1-2) : 92 - 104
  • [25] YIM YS, 1991, CANCER, V67, P2058, DOI 10.1002/1097-0142(19910415)67:8<2058::AID-CNCR2820670808>3.0.CO
  • [26] 2-G